Ayala Pharmaceuticals AL102 gets FDA fast track status in desmoid tumors
Ayala Pharmaceuticals has been granted fast track designation for its oral gamma-secretase inhibitor AL102 by the US Food and Drug Administration (FDA) for the treatment ... Read More
Marker Therapeutics gets FDA approval for MT-601 IND in r/r NHL
Marker Therapeutics said that the US Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for MT-601 for the treatment of ... Read More
AstraZeneca, Daiichi Sankyo get Enhertu FDA approval for HER2-low metastatic breast cancer
Enhertu FDA approval : AstraZeneca and Daiichi Sankyo have secured approval for Enhertu (trastuzumab deruxtecan) from the US Food and Drug Administration for the treatment ... Read More
Innovent Biologics, Sanofi to expedite development of cancer drugs in China
Chinese biopharma company Innovent Biologics and French pharma giant Sanofi have entered into a partnership that aims to bring innovative drugs to patients in China ... Read More
BriaCell Therapeutics gets license for anti-cancer agent sCD80 from UMBC
BriaCell Therapeutics has signed an exclusive licensing deal with the University of Maryland, Baltimore County (UMBC) to develop and commercialize Soluble CD80 (sCD80) as a ... Read More
HUTCHMED begins HMPL-A83 phase 1 trial in advanced malignant neoplasms
HUTCHMED (China) has launched a phase 1 clinical trial of its oncology drug candidate HMPL-A83 in China in patients having advanced malignant neoplasms. HMPL-A83 is ... Read More
Lantern Pharma gets FDA nod for Harmonic phase 2 clinical trial of LP-300
Lantern Pharma said that the US Food and Drug Administration (FDA) has authorized it to move ahead with its Harmonic phase 2 clinical trial of ... Read More
Prescient Therapeutics gets FDA orphan drug status for PTX-100 in PTCL
Prescient Therapeutics has secured the orphan drug designation for its PTX-100 compound from the US Food and Drug Administration (FDA) for the treatment of peripheral ... Read More
AstraZeneca to acquire US biotech firm TeneoTwo for up to $1.27bn
UK-based pharma giant AstraZeneca has signed a deal worth up to $1.27 billion to acquire American biotech company TeneoTwo in a move to bolster its ... Read More
Aura Biosciences gets FDA fast track status for belzupacap sarotalocan
Aura Biosciences has secured fast track designation for belzupacap sarotalocan (AU-011) from the US Food and Drug Administration (FDA) for the treatment of non-muscle invasive ... Read More